A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of BIIB059 in Adult Participants With Active Systemic Lupus Erythematosus Receiving Background Nonbiologic Lupus Standard of Care
Latest Information Update: 19 Jun 2024
At a glance
- Drugs Litifilimab (Primary)
- Indications Systemic lupus erythematosus
- Focus Registrational; Therapeutic Use
- Acronyms TOPAZ-2
- Sponsors Biogen
- 13 Jun 2023 Planned End Date changed from 28 Nov 2025 to 5 Mar 2026.
- 13 Jun 2023 Planned primary completion date changed from 13 Jun 2025 to 18 Sep 2025.
- 30 Jul 2021 Status changed from not yet recruiting to recruiting.